British Pharmacopeia 2009 launches in the UK

12 January 2009

The 2009 edition of the British Pharmacopeia has become effective in the UK from the start of the year. First published in 1864, the BP contains  over 3,200 monographs for pharmaceutical substances, formulated  preparations and other articles used in the practice of medicine.

New to the 2009 edition are 44 monographs for formulated preparations  including veterinary medicines and additional standards for widely-used  unlicensed formulations. All European Pharmacopeia sixth edition  material up to and including Supplement 6.2 is integrated into the text  of the BP 2009. In addition to the expanding number of monographs for  licensed formulated products, the BP supports the regulatory work in the  fields of herbal and complementary medicines by providing new and  revised monographs for herbal medicinal products and for homeopathic  stocks and tinctures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight